Concepedia

Isao Kinoyama

IK

Statistics

Publications

12

Citations

1K

H-Index

11

Active since

1992

Affiliations

Astellas Pharma (Japan)(Current)

Drug Discovery Laboratory (Norway)

Scripps Research Institute

Isao Kinoyama is an author at Astellas Pharma (Japan) specializing in pharmacology, survivin inhibition, and medicine.

Publications per year

1992–2012

12

Publications

12

YM155, a Novel Small-Molecule Survivin Suppressant, Induces Regression of Established Human Hormone-Refractory Prostate Tumor Xenografts

Takahito Nakahara, Masahiro Takeuchi, Isao Kinoyama et al. · Cancer Research · 2007 · 506 citations

, , +17

Broad spectrum and potent antitumor activities of YM155, a novel small‐molecule survivin suppressant, in a wide variety of human cancer cell lines and xenograft models

Takahito Nakahara, Aya Kita, Kentaro Yamanaka et al. · Cancer Science · 2010 · 165 citations

, , +14

Sepantronium Bromide (YM155) induces disruption of the ILF3/p54nrb complex, which is required for survivin expression

Tomohiro Yamauchi, Naoto Nakamura, Masashi Hiramoto et al. · Biochemical and Biophysical Research Communications · 2012 · 71 citations

, , +6

Interleukin Enhancer-binding Factor 3/NF110 Is a Target of YM155, a Suppressant of Survivin

Naoto Nakamura, Tomohiro Yamauchi, Masashi Hiramoto et al. · Molecular & Cellular Proteomics · 2012 · 66 citations · Full text

, , +14

YM155, a novel survivin suppressant, enhances taxane-induced apoptosis and tumor regression in a human Calu 6 lung cancer xenograft model

Takahito Nakahara, Kentaro Yamanaka, Shinji Hatakeyama et al. · Anti-Cancer Drugs · 2011 · 65 citations

, , +17

1–5 of 12